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Non-neuronal cholinergic activity is
potentiated in myasthenia gravis
Bin Han1, Chao Zhang1, Shoufeng Liu2, Yiping Xia3, Hao Sun4, Zhongying Gong5, Alain R. Simard6, Qiang Liu1,7
and Junwei Hao1*
Abstract
Background: Non–neuronal acetylcholine (ACh) restricts autoimmune responses and attenuates inflammation by
cholinergic anti-inflammation pathway. To date, the implication of ACh in myasthenia gravis (MG) remained
unexplored. This study aimed to investigate the possible relationship between ACh levels, anti–muscle-specific
tyrosine kinase (MuSK) antibody titers, main clinical features and outcomes of MG patients.
Methods: We successfully measured ACh levels in human peripheral blood mononuclear cells (PBMCs) from 125
MG patients and 50 matched healthy controls by using ultra-performance liquid chromatography-tandem mass
spectrometry (UPLC-MS/MS). We assessed the quantitative MG (QMG) scores for each patient and titered anti-MuSK
antibody.
Results: We found that PBMC-derived ACh level was significantly higher in MG patients, especially in patients of
class III, IV-V, compared with that in controls (0.142 ± 0.108 vs. 0.075 ± 0.014 ng/million cells, p = 0.0003) according to
the Myasthenia Gravis Foundation of America clinical classification. Importantly, we also found that ACh levels were
positively correlated with QMG scores (r = 0.83, p < 0.0001) and anti–MuSK Ab levels (r = 0.85, p < 0.0001).
Conclusions: Our demonstration of elevated ACh levels in PBMCs of MG patients foreshadows potential new
avenues for MG research and treatment.
Keywords: Acetylcholine, Myasthenia gravis, Inflammation, Cholinergic anti-inflammatory pathway
Background
Myasthenia gravis (MG) is a well-recognized autoimmune
disorder affecting neuromuscular junction [1, 2]. Inflam-
matory environment plays a crucial role in the progress of
this disease [3], appropriate interference with inflamma-
tion is a very promising therapeutic strategy and requires
further research.
Recently, studies regarding the immune-modulating
properties of acetylcholine (ACh) derived from non-
neuronal cells has prompted an increasing interest in the
field of the cholinergic anti-inflammatory pathway. Interest-
ingly, non-neuronal ACh and main components of the cho-
linergic system, such as choline acetyltransferase (ChAT),
acetylcholinesterase (AChE), vesicular acetylcholine trans-
porter (VAChT) and high-affinity choline transporter
(ChT1), are expressed in multiple human cell types,
including keratinocytes [4], pancreatic cells [5] and
immune cells [6]. For instance, ACh released by
ChAT+ B cells limits local neutrophil recruitment to
modulate innate immunity during sterile endotoxemia
[7]. Additionally, ACh-producing T cells in the spleen, in-
duced by vagus nerve stimulation, are known to decrease
the intensity of inflammatory responses through the inhib-
ition of TNF–α production [8]. Lymphocyte-derived ACh
may thus play a key role in the interaction between the
nervous system and immune system to restore homeosta-
sis, a mechanism called the ‘cholinergic anti-inflammatory
pathway’ [9, 10]. Targeting this pathway, which reduces
pro-inflammatory cytokine secretion, was effective in
many experimental animal models, including inflamma-
tory bowel disease [11], experimental autoimmune en-
cephalomyelitis (EAE) [12–16], arthritis [17], ischemia-
reperfusion injury [18], sepsis [19, 20], pancreatitis [21],
myocardial ischemia [22] and hemorrhagic shock [23].
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These studies suggest a tight inter-relationship between
non-neuronal ACh and inflammatory reactions. However,
peripheral cholinergic function related to ACh has not
been investigated in MG till now.
These observations brought us to question whether
human PBMC-derived ACh play a critical role in the
process of MG. Here, we described a simple and stable
ultra-performance liquid chromatography-tandem mass
spectrometry (UPLC-MS/MS) method of our design for
quantifying ACh levels in peripheral blood mononuclear
cells (PBMCs). In addition, we investigated the relation-
ships between ACh levels and MG severity.
Methods
Subjects
This study was approved by institutional review boards
from Tianjin Medical University General Hospital, Tianjin
Huanhu Hospital, Shandong Provincial Hospital Affiliated
to Shandong University and Tianjin First Center Hospital.
Informed consent was obtained from all participants prior
to inclusion. For this study, 125 eligible patients diagnosed
with MG for the first time and 50 matched healthy indi-
viduals were enrolled from April 2015 to May 2016. The
optimum diagnosis of MG was based on a combination of
patients’ clinical manifestations, abnormal electrodiagnos-
tic studies on single-fiber electromyography testing, ab-
normal repetitive nerve stimulation and previous response
to treatment. Aberrant levels of anti-acetylcholine recep-
tor (AChR) and anti–muscle-specific tyrosine kinase
(MuSK) antibodies supported the diagnosis; however, a
seronegative antibody titer was considered insufficient to
refute the diagnosis of MG. All the patients received no
cholinesterase inhibitors and immunosuppressive agents
before definite diagnosis of MG. Exclusion criteria in-
cluded patients with cardiovascular and cerebrovascular
diseases, coagulation disorders, pregnancy, other disorders
causing weakness or fatigue, combined with other
autoimmune diseases, history of malignant disease ex-
cept for thymus, inability to provide informed con-
sent. MG subtyping followed the Myasthenia Gravis
Foundation of America (MGFA) clinical classification,
and the severity of disease and effectiveness of treat-
ment were assessed by a validated quantitative MG
Scoring system (QMG Score) [24].
Isolation of human PBMCs
Before patients receiving treatment, venous blood sam-
ples were extracted into ice-cold tubes containing EDTA
and centrifuged immediately thereafter at 3000 rpm
for 10 min, separating the samples into two layers.
The upper layer, plasma, was subpackaged and stored
at -80 °C for further analysis. The lower layer, precipi-
tated blood cells, was the source of PBMCs isolated
with Ficoll density gradients.
Detection of PBMC-derived intracellular ACh by UPLC–MS/MS
A stable method developed by our team was used to de-
tect ACh levels [25]. Briefly, the fresh PBMCs were sepa-
rated from blood and added to 100 μL deionized H2O/
0.1% formic acid (vol:vol), and vortexed for 15 s to
make homogenate, which was de-proteined by adding
300 μL acetonitrile containing isotope internal stand-
ard (D9-ACh, C/D/N, Quebec, Canada). The sample
was vortexed again for 1 min then centrifuged at
15000 rpm for 10 min. The supernatant was trans-
ferred to a sterile autosampler glass vials for measure-
ment. The recovery of ACh following the sample
cleanup procedure, as estimated from the pre and
post cleanup standard curves, was 96.5%.
For highly specific and sensitive measurement of intra-
cellular ACh, we used an Acquity UPLC system coupled
to a Xevo TQ-S (Waters Corporation, Milford, MA,
USA). ACh was separated by liquid chromatography
using a CORTECS HILIC column (1.7 μm, 100 mm ×
2.1 mm). Serially diluted ACh was used to construct a
standard curve. All standards and samples received a
uniform aliquot of D9-ACh internal standard to correct
for variations in extraction efficiency.
Anti-AChR and anti–MuSK Ab titering
Anti-AChR and anti–MuSK Ab levels in the blood
plasma were determined in duplicates, and mean values
calculated, by ELISA (Trust Specialty Zeal, USA [AChR
Ab assay range: 6 pmol/L-1200 pmol/L; MuSK Ab assay
range: 2 U/L-400 U/L]) according to the manufacturer’s
instructions.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from fresh human PBMCs
with the TRIzol reagent (Invitrogen, USA) according to
the manufacturer’s protocol. Reverse transcription reac-
tions were carried out with TransScript First-Strand
cDNA Synthesis Super Mix (TransGen Biotech, China)
according to the supplied protocol. qPCR reactions were
all performed in triplicate. FastStart Universal SYBR
Green Master (Roche, Germany) was used as the detec-
tion dye. We used β-actin as an internal reference gene
to normalize the expression level for AChE, ChAT,
ChT1 and VAChT. The amplification and detection of
specific products were performed with the CFX Con-
nectTM Real-Time System (Bio-Rad, USA). PCR condi-
tions were the following: denaturation at 95 °C for
10 min, followed by 39 cycles of 95 °C for 15 s, 58-61 °C
for 30 s, 72 °C for 20 s, and a final extension step of 72 °C
for 10 min. The mean value was calculated by plot-
ting Ct, and then used for further calculation. The
mean relative expression was gained by the 2-△△Ct compara-
tive method. The primers for amplification were the follow-
ing: 5′-GGGTGGTAGACGCTACAACC-3′ (forward) and
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5′-GTGCCCTCAAAACCTGGGTAT-3′ (reverse) for
AChE, 5′- AACCACGGAGATGTTCTGCTGCTAT-3′
(forward) and 5′- TTGTTGCCAATGGCTTGCTCTC
AG-3′ (reverse) for ChAT, 5′-ATCCCAGCCATACT-
CATTGG-3′ (forward) and 5′-CAGAAACTGCACCAA
GACCA-3′ (reverse) for ChT1, 5′- GGCATAGCCCTAG
TCGACAC-3′ (forward) and 5′-CGTAGGCCACCGAA
TAGGAG-3′ (reverse) for VAChT.
Western blot analysis
Human PBMCs were lysed in RIPA (Solarbio) coupled
with PMSF, a protease inhibitor. Afterward, we detected
protein concentrations using BCA protein assay reagent;
the equal protein samples were then mixed with 4 ×
sample buffer and boiled for 10 min. The samples were
separated by 10% SDS-PAGE gel and transferred onto
PVDF membranes (Millipore, USA) by the semi-dry
transfer method. After blocking in 5% nonfat dried milk
in TBST for 2 h at room temperature, the blots were
incubated with specific antibodies overnight at 4 °C.
After washing, the membranes were incubated with
secondary antibodies for 1 h at room temperature.
The specific protein bands were detected using a Bio-
Rad Gel Doc Imager. The specific antibodies (Santa
Cruz, CA, USA) included were mouse anti-AChE
(1:100), mouse anti-ChAT (1:100) and goat anti-VAChT
(1:1000). The relative amounts of proteins were normal-
ized against GAPDH.
Determination of cholinergic components in PBMCs by
ELISA
Human PBMCs were lysed, and total protein concentra-
tion of the lysates was determined by BCA method. The
levels of AChE, VAChT and ChAT proteins were then
measured by ELISA (Shanghai Yuanye biological tech-
nology co., LTD, Shanghai, China) according to the man-
ufacturers’ instructions. All samples and standards were
determined in duplicate. All data were calculated and
normalized to the total protein concentration in each
sample.
Statistical analysis
Statistical analysis was performed using SPSS Statistics
20.0 (IBM Corp, USA. Released 2011). Data are
expressed as means ± SD. For data with normal distribu-
tion, one-way analysis of variance with Dunnet test was
used to assess the differences among groups. An
independent-sample t test was used to compare differ-
ences between two groups. For data with nonnormal dis-
tribution, the Mann–Whitney U tests to compare
differences between two groups. Kruskal-Wallis test was
applied to test for mutiple groups. Repeated measures
ANOVA was used to compare differences before and
after treatment. Regression analysis was conducted to
test for associations between parameters (ACh, QMG
scores and anti–MuSK Ab concentrations). Values of
p < 0.05 were considered to be statistically significant.
Results
Baseline characteristics
The characteristics of all participants enrolled in this
study were shown in Table 1. There were no statistically
significant differences in age, or gender in the MG pa-
tients as compared with healthy controls. In addition, we
have shown the treatment plan after blood drawing in
this table.
PBMC-derived ACh content changed in MG patients
compared with controls
We first established that UPLC-MS/MS was a precise,
stable and available technique to detect intracellular
ACh then used this method routinely to determine the
PBMC-derived ACh content of our MG patients. To
eliminate the influence of cholinesterase inhibitors, we
assessed ACh levels by preprocessing PBMCs with eser-
ine, a cholinesterase inhibitor, for 30 min in the vacuette
blood collection tubes once blood samples were drawn
and compared MG patients untreated or treated with
pyridostigmine (Additional file 1). We did not find sta-
tistically significant differences (p > 0.05). Eight patients
were in each group, and the two groups showed no sig-
nificant differences in QMG score (2.00 ± 1.604 vs. 1.75
± 1.488, p = 0.7513). Subsequently, we recorded signifi-
cantly higher levels of ACh per million cells in MG pa-
tients compared with controls (0.142 ± 0.108 vs. 0.075 ±
0.014 ng/million cells, p = 0.0003) (Fig. 1a). Similarly,
amount of relative mRNA expression for ChT1, the rate-
limiting enzyme for ACh, was higher in samples from
MG patients than those from controls (p = 0.0449)
(Fig. 1b). However, there was no statistical significance
for ChAT, a direct synthetase for ACh, mRNA expres-
sion (p = 0.9061) (Fig. 1c). The MG group contained dra-
matically less AChE, a degrading enzyme for ACh,
mRNA than in controls (p = 0.0011) (Fig. 1d).
Intracellular ACh levels in relation to MG severity
Based on these findings, we further defined whether ACh
levels differ in patients with varied subtypes of MG as
classified by the MGFA. ACh content was significantly ele-
vated in patients with class III-V MG (p < 0.0001), but not
those in class I-II, compared with controls (Fig. 2a). In
support, a positive correlation was found between ACh
levels and QMG scores in our cohort (r = 0.83, p < 0.0001)
(Fig. 2b). Meanwhile, correlation between MGFA classifi-
cation and the QMG score in MG patients (n = 125)
was assessed using the Spearman rank correlation
analysis, and positive correlation was observed between
them (r = 0.874, p < 0.001). Also, we observed that ACh
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levels had declined significantly in patients two weeks
after the initial treatment (0.286 ± 0.077 vs. 0.167 ± 0.064,
p < 0.0001) (Fig. 2c). Eighteen of these patients were
treated with pyridostigmine, IVIG and oral prednisone,
while others were treated with pyridostigmine, IVIG and
IV methylprednisolone. Further, disease severity evaluated
by QMG scores before and after treatment with immuno-
logical therapy decreased at the post-treatment period to
the level of statistical significance (14.20 ± 5.176 vs. 9.07 ±
3.562, p < 0.0001) (Fig. 2d). Therefore, our data showing
that immunological therapy was effective treatment is
consistent with previous studies [26, 27]. We also quantified
the anti-AChR and anti–MuSK Ab levels in the plasma of
MG patients. No significant association was found between
anti-AChR Ab levels and ACh levels (r= 0.22, p= 0.1673)
(Fig. 3a), however, the ACh levels correlated positively with
anti–MuSK Ab levels (r= 0.85, p < 0.0001 by regression ana-
lysis) (Fig. 3b). In our cohort, the anti–MuSK Ab concentra-
tions increased as MG worsened (p= 0.0135 by Kruskal-
Wallis) (Fig. 3c). Meanwhile, a positive correlation was
found between the anti–MuSK Ab levels and QMG scores
(r = 0.69, p = 0.0046 by regression analysis) (Fig. 3d).
In addition, we found that the ACh levels are significantly
elevated in anti-MuSK Ab positive group compared
with double-negative and anti-AChR Ab-positive
groups (p < 0.001, p < 0.01, respectively). However,
there was no significant statistical differ ence between
double-negative and anti-AChR Ab-positive groups
Table 1 Comparative demographics of patients with MG and controls
Characteristics MGFA Classification Control
I II III IV-V
NO. of samples(n) 58 30 24 13 50
Age (years) 46.10 ± 9.45 43.80 ± 10.83 45.63 ± 10.94 48.23 ± 9.65 46.14 ± 9.89
Female n (%) 28 (48.3) 15 (50.0) 10 (54.2) 5 (45.5) 26 (52.0)
AChR Ab pos n (%) 42 (72.4) 20 (66.7) 17 (70.8) 7 (53.8) NA
MuSK Ab pos n (%) 3 (5.2) 3 (10.0) 4 (16.7) 5 (38.5) NA
Double negative n (%) 13 (22.4) 7 (23.3) 3 (12.5) 1 (7.7)
Treatment Pyridostigmine, 23 of 58
added oral Prednisone
Pyridostigmine, 25 of 28
added oral Prednisone
Pyridostigmine, IVIG,
Subsequent oral prednisone
Pyridostigmine, IVIG,
IV methylprednisolone
NA
MG myasthenia gravis, AChR Ab acetylcholine receptor antibody, MuSK Ab muscle-specific tyrosine kinase antibody, I to V according to Myasthenia Gravis Founda-
tion of America (MGFA) clinical classification; NA not available
Fig. 1 PBMC-derived ACh and cholinergic content differs in patients with MG from that in healthy controls. a PBMC-derived ACh per million cells
was obviously increased in MG patients (n = 125) compared with controls (n = 50) (p = 0.0003). b High-affinity choline transporter (ChT1) mRNA
expression was higher in MG patients (n = 15) than that in control (n = 6) (p = 0.0449). c Choline acetyltransferase (ChAT) mRNA relative expression
showed no obvious change (p = 0.9061). d A sharp decrease in acetylcholinesterase (AChE) mRNA expression was observed between MG patients
and controls (p = 0.0011). (c-d; n = 10 for control, n = 36 for MG)
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(p > 0.05) (Fig. 3e). Overall, some of our findings are
in accord with those from previous studies [28–30].
The increased ACh levels denoted that cholinergic ac-
tivity is potentiated and increased ACh levels may re-
flect an inflammatory status in patients with MG.
Cholinergic components in PBMCs
When we further explored discrepancies of choliner-
gic components in PBMCs from MG patients and
controls, the relative expression of intracellular AChE
and VAChT mRNA had decreased significantly in
class III-V patients (p = 0.0130, p = 0.0091, respectively)
(Fig. 4a-b). Yet we did not observe a statistically significant
increase in ChAT mRNA expression (p = 0.2175) (Fig. 4c).
These mRNA levels were similar to the corresponding
proteins assessed by Western blotting (Fig. 4d). In
addition, the levels of these three proteins in PBMCs
were also measured by ELISA. The protein concentra-
tions conformed to the show in Western blotting
(Fig. 4e-g). These data thus indicate that the choliner-
gic activity was changed and the higher ACh levels
observed in MG patients perhaps resulted from lower
AChE expression.
Discussion
Our principal findings in this study are that ACh levels
increase prominently in PBMCs from patients with MG
exceeding those from healthy individuals and ACh likely
correlates with the severity of MG. The up-regulated
ACh may enhance the lymphocytes’ ability to counteract
inflammation via cholinergic signaling to restore homeo-
stasis. Moreover, we observed elevations of circulating
anti-MuSK Ab concentrations in MG patients with more
serious clinical symptoms, which was accordance with a
previous study [29]. Since non-neuronal ACh play an
important role in immune regulation, an outcome that
likely designates ACh as a possible homeostatic marker
induced by the inflammatory reaction in MG.
Experimental evidence indicates that non-neuronal
ACh profoundly modulates the innate immune system
[7, 31] by binding to nicotinic AChRs such as those that
inhibit cytokine release, ameliorate tissue injury and at-
tenuate cytokine-mediated effects in experimental sepsis,
endotoxemia and other inflammatory syndromes [8, 32,
33]. On the other hand, the cholinergic anti-inflammatory
pathway may be activated by an inflammatory response
[10]. Since the roles of PBMC-derived ACh in MG were
not previously studied, our study may help to explore the
Fig. 2 PBMC-derived ACh levels correlate positively with MG severity. a Histogram shows that ACh concentrations per million cells increased
along with MG severity according to the MGFA clinical classification (n = 50 for control, n = 58 for class I, n = 30 for class II, n = 24 for class III, n = 13
for class IV-V) (p < 0.0001). b ACh level distribution relative to QMG scores (n = 125) (p < 0.0001). c ACh content decreased in patient’s blood drawn
before treatment and 2 weeks after initial treatment, respectively (p < 0.0001). d QMG scores also decreased in patients (p < 0.0001). (c-d; n = 30
in each group)
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mechanism of MG from a different aspect. Indeed,
PBMC-derived ACh levels were significantly higher in
MG patients compared with those in healthy controls,
particularly higher in class III-V patients according to the
MGFA clinical classification. These differences may be
caused by the extent of disease, since anti-inflammatory
responses are usually determined by the magnitude of the
inflammatory response [10]. Under inflammatory condi-
tions in MG, the vagus nerve may be activated by pro-
inflammatory cytokines, which could potentiate ACh pro-
duction by splenic lymphocytes. Therefore, increasing
ACh levels in PBMCs likely reflects MG-induced cho-
linergic hyperexcitation, which potentially serves as
endogenous protection from excessive inflammatory
reactions. Activation of ACh, therefore, represents a
promising therapeutic strategy to improve cholinergic
anti-inflammatory function and combat inflammation.
In humans, accumulating evidence indicates that
AChE is directly or indirectly involved in the regulation
of inflammatory responses or functions as a predictor of
inflammation, usually correlated with multiple inflam-
matory markers, such as those in patients with inflam-
matory bowel disease [34] or stroke [35]. Presently,
AChE inhibitors are used to interfere with the break-
down of ACh and impact the cholinergic system, such as
in MG patients. In this current study, AChE expression
was significantly lower in patients with MG than in their
healthy counterparts, indicating a possible role of ACh
content and AChE in regulating inflammation in MG
patients.
To explore the potential relevance of ACh levels in the
regulation of inflammation in MG, we further conducted
a correlation analysis. Surprisingly, we found that ACh
levels correlated positively with QMG scores as well as
anti-MuSK Ab titers of MG patients. Actually, anti-
MuSK-positive patients have a higher frequency of se-
vere clinical symptoms [29]. As previously reported,
quantities of anti-MuSK antibodies increased along with
MG severity according to the MGFA clinical classifica-
tion, and correlated with QMG scores in our cohort. As
also demonstrated here, the more severe states of disease
paralleled the higher PBMC-derived ACh concentra-
tions. We then found that the trend of PBMC-derived
ACh content and QMG scores declined in patients after
treatment with immunotherapy, which maybe result
from the declined cholinergic excitation when patients
were in a relatively stable state after treatment. On the
other hand, the immunotherapy may influenced the
synthesis, storage and degradation of ACh. We there-
fore speculate that an endogenous ACh-mediated
Fig. 3 PBMC-derived ACh is positively associated with anti-MuSK Ab concentrations. a No correlation was found between ACh levels and anti-
AChR antibodies (n = 40) (p = 0.1673). b A positive correlation was found between ACh levels and anti-MuSK antibodies (n = 15) (p < 0.0001 by re-
gression analysis). c Histogram shows that anti-MuSK Ab concentrations relative to MG severity (n = 3 for class I and II, n = 4 for class III, n = 5 for
class IV-V) (p = 0.0135 by Kruskal-Wallis). d Anti-MuSK Ab distributions in relation to QMG scores (n = 15) (p = 0.0046 by regression analysis). e The
ACh levels were higher in anti-MuSK Ab-positive group than that in double-negative and anti-AChR Ab-positive groups (n = 24 in double-
negative group, n = 86 in anti-AChR Ab-positive group, n = 15 in anti-MuSK Ab-positive group) (p < 0.001, p < 0.01, respectively)
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anti-inflammatory pathway may be launched in an at-
tempt to restore homeostasis in MG patients. How-
ever, the fact that anti-MuSK Ab levels remained
high suggests that, despite higher levels of ACh, this
pathway is not sufficient to reverse disease pathology,
possibly due to their limited number [19].
Some limitations of our study must be addressed. First,
studies in vivo and in vitro are still necessary to deter-
mine the relationships among all these components. Sec-
ond, the changes of ACh might result from other factors
that influence the cholinergic system, such as infection,
age or emotion. Further studies should determine their
contributions, if any.
Conclusions
Accumulating evidence suggests that non-neuronal ACh
has immunomodulatory effects. Interestingly, we found
that elevations in PBMC-derived ACh levels accompanied
increasingly severe MG, which may be induced by inflam-
matory reflex and depend on the magnitude of the inflam-
matory response. Intervention in cholinergic activity may
change the course of this disease. The decline of disease
severity after treatment with immunotherapy indicates
that ACh levels may be valuable for monitoring the pro-
gression or treatment efficacy of MG, which larger and
well- defined cohort studies should confirm.
Additional file
Additional file 1 Detection stability of the ACh levels in PBMCs. a
The ACh levels were not changed in PBMCs after pre-adding eserine,
a cholinesterase inhibitor, to the peripheral blood sample (n = 4 in
each group) (p = 0.8857). b The levels of ACh in PBMCs were not
significantly different between untreated and treated MG patients
with pyridostigmine (n = 8 in each group) (p = 0.9768). (PPTX 117 kb)
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ACh: Acetylcholine; AChE: Acetylcholinesterase; AChR: Acetylcholine
receptor; ChAT: Choline acetyltransferase; ChT1: High-affinity choline
transporter; MG: Myasthenia gravis; MGFA: Myasthenia Gravis Foundation
of America; MuSK: Muscle-specific tyrosine kinase; QMG: Quantitative MG;
UPLC-MS/MS: Ultra-performance liquid chromatography-tandem mass
spectrometry; VAChT: Vesicular acetylcholine transporter
Fig. 4 Cholinergic components change in MG patients versus controls. a The expression of AChE mRNA was significantly declined in MG
patients, especially class III-V, compared with controls (p = 0.0130 by Kruskal-Wallis). b The VAChT mRNA expression also decreased in MG patients
(p = 0.0091 by Kruskal-Wallis). c There was no obvious change about the ChAT mRNA expression (p = 0.2175 by Kruskal-Wallis). d Western blots
were used to assess levels of the corresponding proteins showing a similar tendency. e AChE protein expression in PBMCs detected by ELISA was
significantly decreased in class III and class IV-V groups compared with control (p < 0.05, p < 0.01, respectively). The data were presented as U of
AChE per mg protein. f VAChT expression was also reduced, especially in class III-V group (p < 0.05), compared with control. The data were pre-
sented as ng of VAChT per mg protein. g The level of ChAT in PBMCs was not significantly different among these groups (p = 0.3271). The data
were presented as pg of ChAT per mg protein. (a-c; n = 10 in the control, class I, class II and class III groups, n = 6 in the class IV-V group) (d-g; n
= 5 in each group)
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